Why Arbutus Stock Is Trading Higher Today

Arbutus Biopharma Corp ABUS shares were trading higher Tuesday after the company reported continued positive data from an ongoing Phase 1a/1b clinical trial with AB-729.

The new data demonstrates that in chronic hepatitis B subjects, a single, subcutaneous 90mg injection of AB-729 resulted in a mean HBsAg reduction of 1.23 log₁₀ IU/mL at week 12. 

Arbutus Biopharma is a biopharmaceutical company focused on hepatitis B. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing of lipid nanoparticle technology.

Arbutus shares were trading up 13.02% at $2.96 at the time of publication Tuesday. The stock has a 52-week high of $9.02 and a 52-week low of 82 cents.